References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424. doi: 10.3322/caac.21492
- Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-53. doi: 10.1002/ijc.31937
- Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-44. doi: 10.1200/JCO.2005.04.4859
- Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, Møller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 2012; 75: 280-4. doi: 10.1016/j.lungcan.2011.08.004
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8: 1563-74. doi: 10.1200/JCO.1990.8.9.1563
- Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007; 12: 1096-104. doi: 10.1634/theoncologist.12-9-1096
- Yang Y, Yuan G, Zhan C, Huang Y, Zhao M, Yang X, et al. Benefits of surgery in the multimodality treatment of stage IIB-IIIC small cell lung cancer. J Cancer 2019; 10: 5404-12. doi: 10.7150/jca.31202
- Lassen U, Østerlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J Clin Oncol 1995; 13: 1215-20. doi: 10.1200/JCO.1995.13.5.1215
- Kato Y, Ferguson TB, Bennett DE, Burford TH. Oat cell carcinoma of the lung. A review of 138 cases. Cancer 1969; 23: 517-24. 10.1002/1097-0142(196903)23:3<;517::aid-cncr2820230301>3.0.co;2-l
- Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017; 18: 1116-25. doi: 10.1016/S1470-2045(17)30318-2
- Simone CB 2nd, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, et al. Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline. Pract Radiat Oncol 2020; 10: 158-73. doi: 10.1016/j.prro.2020.02.009
- Stanic K, Vrankar M, But-Hadzic J. Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy. Radiol Oncol 2020; 29; 54: 353-63. doi: 10.2478/raon-2020-0046
- Tian S, Zhang X, Jiang R, Pillai RN, Owonikoko TK, Steuer CE, et al. Survival outcomes with thoracic radiotherapy in extensive-stage small-cell lung cancer: a propensity score-matched analysis of the national cancer database. Clin Lung Cancer 2019; 20: 484-93.e6. doi: 10.1016/j.cllc.2019.06.014
- Tay RY, Heigener D, Reck M, Califano R. Immune checkpoint blockade in small cell lung cancer. Lung Cancer 2019; 137: 31-7. doi: 10.1016/j.lungcan.2019.08.024
- Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379: 2220-9. doi: 10.1056/NEJMoa1809064
- Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394: 1929-39. doi: 10.1016/S0140-6736(19)32222-6
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44. doi: 10.1038/nature07205
- Tan CSY, Read JA, Phan VH, Beale PJ, Peat JK, Clarke SJ. The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. Support Care Cancer 2015; 23: 385-91. doi: 10.1007/s00520-014-2385-y
- Zheng J, Seier K, Gonen M, Balachandran V, Kingham T, D’Angelica M, et al. Utility of serum inflammatory markers for predicting microvascular invasion and survival for patients with hepatocellular carcinoma. Ann Surg Oncol 2017; 24: 3706-14. doi: 10.1245/s10434-017-6060-7
- Maestu I, Pastor M, Gómez-Codina J, Aparicio J, Oltra A, Herranz C, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997; 8: 547-53. doi: 10.1023/a:1008212826956
- Alexandrakis M, Passam F, Moschandrea I, Christophoridou A, Pappa C, Coulocheri S, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26: 135-40. doi: 10.1097/00000421-200304000-00007
- Petekkaya I, Unlu O, Roach E, Gecmez G, Okoh A, Babacan T, et al. Prognostic role of inflammatory biomarkers in metastatic breast cancer. J BUON 2017; 22: 614-22.
- Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003; 39: 303-13. doi: 10.1016/s0169-5002(02)00508-1
- Haas M, Heinemann V, Kullmann F, Laubender R, Klose C, Bruns C, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 2013; 139: 681-9. doi: 10.1007/s00432-012-1371-3
- Bernhardt D, Aufderstrasse S, König L, Adeberg S, Bozorgmehr F, Christopoulos P, et al. Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy. Cancer Manag Res 2018; 10: 6563-9. doi: 10.2147/CMAR.S180990
- Oh SY, Heo J, Noh OK, Chun M, Cho O, Oh YT. Absolute lymphocyte count in preoperative chemoradiotherapy for rectal cancer: changes over time and prognostic significance. Technol Cancer Res Treat 2018; 17: 1533033818780065. doi: 10.1177/1533033818780065
- Ozmen S, Timur O, Calik I, Altinkaynak K, Simsek E, Gozcu H, et al. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer. Endocr Regul 2017; 51: 131-6. doi: 10.1515/enr-2017-0013
- Acartürk Tunçay E, Karakurt Z, Aksoy E, Saltürk C, Gungor S, Ciftaslan N, et al. Eosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation marker. Int J Chron Obstruct Pulmon Dis 2017; 12: 3361-70. doi: 10.2147/COPD.S147261
- Zhao Q, Yang Y, Xu S, Zhang X, Wang H, Zhang H, et al. Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients. Onco Targets Ther 2015; 8: 2731-8. doi: 10.2147/OTT.S90875
- Yu Y, Qian L, Cui J. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patients. Mol Clin Oncol 2017; 7: 498-506. doi: 10.3892/mco.2017.1342
- Zhao QT, Yuan Z, Zhang H, Zhang X, Wang H, Wang Z, et al. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3,720 patients. Int J Cancer 2016; 139: 164-70. doi: 10.1002/ijc.30060
- Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
- Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi99-vi105. doi: 10.1093/annonc/mdt178
- Sakin A, Sahin S, Yasar N, Demir C, Arici S, Geredeli C, et al. The relation between hemogram parameters and survival in extensive-stage small cell lung cancer. Oncol Res Treat 2019; 42: 506-15. doi: 10.1159/000501595
- Käsmann L, Bolm L, Schild SE, Janssen S, Rades D. Neutrophil-to-lymphocyte ratio predicts outcome in limited disease small-cell lung cancer. Lung 2017; 195: 217-24. doi: 10.1007/s00408-017-9976-6
- Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 2014; 111: 452-60. doi: 10.1038/bjc.2014.317
- Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 2015; 236: 297-304. doi: 10.1620/tjem.236.297
- Go SI, Kim RB, Song HN, Kang MH, Lee US, Choi HJ. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. Med Oncol 2014; 31: 323. doi: 10.1007/s12032-014-0323-y
- Proctor MJ, Morrison DS, Talwar D, Balmer S, Fletcher C, O’reilly D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47: 2633-41. doi: 10.1016/j.ejca.2011.03.028
- Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990; 61: 597-604. doi: 10.1038/bjc.1990.133
- Cao S, Jin S, Shen J, Cao J, Zhang H, Meng Q, et al. Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients. Oncotarget 2017; 8: 8657-69. doi: 10.18632/oncotarget.14395
- Lohinai Z, Bonanno L, Aksarin A, Pavan A, Megyesfalvi Z, Santa B, et al. Neutrophil–lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. Peer J 2019; 7: e7232. doi: 10.7717/peerj.7232
- Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, et al. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol 2018; 126: 499-505. doi: 10.1016/j.radonc.2017.12.030
- Pan Z, Zhang L, Liu C, Huang X, Shen S, Lin X, et al. Cisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selection. Oncol Lett 2019; 18: 1513-20. doi: 10.3892/ol.2019.10459
- Zheng Y, Wang L, Zhao W, Dou Y, Lv W, Yang H, et al. Risk factors for brain metastasis in patients with small cell lung cancer without prophylactic cranial irradiation. Strahlenther Onkol 2018; 194: 1152-62. doi: 10.1007/s00066-018-1362-7
- Wen Q, Meng X, Xie P, Wang S, Sun X, Yu J. Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy. Oncotarget 2017; 8: 81405-18. doi: 10.18632/oncotarget.19073
- Xie D, Marks R, Zhang M, Jiang G, Jatoi A, Garces YI, et al. Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. J Thorac Oncol 2015; 10: 1213-20. doi: 10.1097/JTO.0000000000000585
- Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH. Prognostic significance of total lymphocyte count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in limited-stage small-cell lung cancer. Clin Lung Cancer 2019; 20: 117-23. doi: 10.1016/j.cllc.2018.11.013
- Pan H, Shi X, Xiao D, He J, Zhang Y, Liang W, et al. Nomogram prediction for the survival of the patients with small cell lung cancer. J Thorac Dis 2017; 9: 507-18. doi: 10.21037/jtd.2017.03.121
- Zhang Q, Qu Y, Liu H, Jia H, Wen F, Pei S, et al. Initial platelet-to-lymphocyte count as prognostic factor in limited-stage small cell lung cancer. Biomark Med 2019; 13: 249-58. doi: 10.2217/bmm-2018-0415
- Liu D, Huang Y, Li L, Song J, Zhang L, Li W. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer. BMC Cancer 2017; 17: 882. doi: 10.1186/s12885-017-3893-1
- Wang X, Teng F, Kong L, Yu J. Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. Onco Targets Ther 2016; 9: 5761-70. doi: 10.2147/OTT.S106296
- Mirili C, Guney IB, Paydas S, Seydaoglu G, Kapukaya TK, Ogul A, et al. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC). Int J Clin Oncol 2019; 24: 168-78. doi: 10.1007/s10147-018-1338-8
- Deng M, Ma X, Liang X, Zhu C, Wang M. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget 2017; 8: 37200-7. doi: 10.18632/oncotarget.16553
- Yin X, Yan D, Qiu M, Huang L, Yan SX. Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis. BMC Cancer 2019; 19: 95. doi: 10.1186/s12885-018-5251-3